11 completed, 9 unknown, 2 terminated, 1 recruiting. 24 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 24 | Completed 11, Unknown 9, Terminated 2, Recruiting 1, Withdrawn 1 |
Follow Lactulose: new trials by email Literature Review of Lactulose trials Research Report on Lactulose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE Oral Branched chain Amino acid, Rifaximin 550 MG, Lactulose - Hepatic Encephalopathy, Decompensated Cirrhosis | Phase 4 | Recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 336 | 2025-02-01 | 2026-11-17 |
| A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy. Probiotic plus lactulose, Rifaximin plus lactulose, L-ornithine-L-aspartate plus latulose - Overt Hepatic Encephalopathy | Phase 4 | Completed | Qurratul Ain Jamil | 252 | 2024-12-02 | 2025-06-25 |
| Clinical Study on the Application of Lactulose Combined with Linaclotide in Bowel Preparation for Colonoscopy Lactulose, Lactulose+ linaclotide, polyethylene glycol (PEG) - Lactulose, Bowel Preparation | Phase 4 | Unknown | Haifeng Lan | 444 | 2024-09-01 | 2024-12-27 |
| Bowel Preparation in Colonoscopy: Lactulose vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study. Bowel preparation before colonoscopy - Colorectal Cancer Screening | Phase 4 | Completed | Hospital Civil de Guadalajara | 449 | 2024-07-20 | 2026-07-28 |
| Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy Polyethylene Glycols, Lactulose oral solution, L-ornithine L-aspartate - Hepatic Encephalopathy Stage 2, Hepatic Encephalopathy Stage 3 | Phase 4 | Unknown | Jinnah Postgraduate Medical Centre | 360 | 2023-10-01 | 2023-07-13 |
| Effectiveness of Oral Lactulose Versus Lactulose Enema in Hepatic Encephalopathy Tap water, Lactulose - Hepatic Encephalopathy, Chronic Liver Disease | Phase 4 | Unknown | Khyber Medical College, Peshawar | 100 | 2023-04-01 | 2023-04-05 |
| Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders Linaclotide, Lactulose, Omeprazol - Functional Dyspepsia, Constipation-predominant Irritable Bowel Syndrome | Phase 4 | Unknown | RenJi Hospital | 78 | 2021-01-01 | 2021-12-13 |
| Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial) Polyethylene Glycols, Lactulose - Hepatic Encephalopathy | Phase 4 | Unknown | Aga Khan University | 102 | 2020-03-09 | 2023-04-19 |
| Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea Ondansetron 8mg, abdominal MRI, Lactulose - Motility Disorder of Intestine, Ondansetron | Phase 4 | Completed | University of Nottingham | 16 | 2018-10-16 | 2019-11-27 |
| PEG3350 in ACLF With Hepatic Encephalopathy PEG-3350 with Electolytes, Lactulose - Hepatic Encephalopathy, Acute-On-Chronic Liver Failure | Phase 4 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 60 | 2018-05-20 | 2019-06-17 |
| Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation Current Bowel Protocol (senna/lactulose), PEG Bowel Protocol (PEG/lactulose) - Constipation, Peritoneal Dialysis Complication | Phase 4 | Completed | Nova Scotia Health Authority | 25 | 2017-07-07 | 2024-08-21 |
| PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Lactulose, Polyethylene Glycol - Hepatic Encephalopathy | Phase 4 | Unknown | Sherief Abd-Elsalam | 100 | 2017-03-11 | 2017-04-27 |
| Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation Prucalopride, Polyethylene glycol (PEG), Lactulose - Constipation | Phase 4 | Completed | Xian-Janssen Pharmaceutical Ltd. | 280 | 2014-10-14 | 2017-09-15 |
| Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding Lactulose, L-ornithine L-aspartate, Rifaximin - Hepatic Encephalopathy | Phase 4 | Completed | Hospital General de Mexico | 88 | 2014-07-01 | 2018-05-22 |
| Quality of Life and Nutritional Improvements in Cirrhotic Patients Rifaximin, Lactulose, Lactulose Placebo - Liver Cirrhosis, Hepatic Encephalopathy | Phase 4 | Terminated | Tampa General Hospital | 4 | 2013-04-01 | 2013-09-23 |
| The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy Rifaximin, Lactulose - Hepatic Encephalopathy, Cirrhosis | Phase 4 | Completed | Bausch Health Americas, Inc. | 222 | 2013-01-08 | 2019-09-09 |
| A Preference Study Comparing Kristalose® and Liquid Lactulose lactulose (Kristalose®), liquid lactulose - Constipation | Phase 4 | Completed | Cumberland Pharmaceuticals | 50 | 2009-06-01 | 2011-09-27 |
| Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy L-ornithine-L-aspartate and lactulose, placebo and lactulose - Hepatic Encephalopathy | Phase 4 | Completed | Mahidol University | 35 | 2008-09-01 | 2020-09-04 |
| Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Lactulose, Probiotics(VSL#3) - Hepatic Encephalopathy | Phase 4 | Unknown | Govind Ballabh Pant Hospital | 2008-09-01 | 2010-08-10 | |
| Rifaximin Versus Lactulose in Renal Failure Rifaximin, Lactulose - Liver Cirrhosis, Renal Failure | Phase 4 | Withdrawn | Weill Medical College of Cornell University | 2008-06-01 | 2022-02-08 |
Showing 20 of 24. Sign in to see all of them.
Hepatic Encephalopathy (13) · Constipation (4) · Liver Cirrhosis (4) · Fibrosis (3) · Hepatic Insufficiency (2) · Liver Diseases (2) · Acute-On-Chronic Liver Failure (1) · Bone Diseases, Metabolic (1) · Brain Diseases (1) · Colorectal Neoplasms (1) · Fissure in Ano (1) · Hemorrhoids (1) · Hypertension, Portal (1) · Irritable Bowel Syndrome (1) · Liver Failure (1)
Post Graduate Institute of Medical Education and Research, Chandigarh (3) · Govind Ballabh Pant Hospital (2) · Solvay Pharmaceuticals (2) · Aga Khan University (1) · Bausch Health Americas, Inc. (1) · Cumberland Pharmaceuticals (1) · Haifeng Lan (1) · Hospital Civil de Guadalajara (1) · Hospital General de Mexico (1) · Jinnah Postgraduate Medical Centre (1) · Khyber Medical College, Peshawar (1) · Mahidol University (1) · Nova Scotia Health Authority (1) · Qurratul Ain Jamil (1) · RenJi Hospital (1)
India (5) · United States (4) · China (3) · Pakistan (3) · Mexico (2) · Spain (2) · Canada (1) · Egypt (1) · Thailand (1) · United Kingdom (1)
Barjesh C Sharma, MD,DM (2) · Aliena Badshah (1) · Amany Abd El-Rahim Abdin, MD (1) · Guy Neff, MD, MBA (1) · Hala Hany Shehata, Msc (1) · Hanan Soliman, MD (1) · Jaclyn Y Tran, BScPharm (1) · Ji Xuan (1) · Lindsey Mathew (1) · Madhumita Premkumar, DM (1) · Om Parkash (1) · QurratulAin Jamil, PhD (1) · Radha K Dhiman, MD,DM, FACG (1) · Robin Spiller (1)
PMID 17326150, PMID 30079329, PMID 33060437, PMID 37467180, PMID 40079184, PMID 41272855